Hikma Pharmaceuticals Plc Holding(s) in Company (4959Q)
February 29 2016 - 8:59AM
UK Regulatory
TIDMHIK
RNS Number : 4959Q
Hikma Pharmaceuticals Plc
29 February 2016
For filings with the FCA
include the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
----------------------------------------------------------------------------------------------------
1. Identity of the issuer or Hikma Pharmaceuticals PLC
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
------------------------------------------------------ --------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights ü
------------------------------------------------------- -------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------- -------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------- -------------------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------- -------------------------------------------
Other (please
specify):
----------------------------------------------------- -------------------------------------------
3. Full name of person(s) Boehringer Ingelheim Corporation;
subject to the Boehringer Ingelheim USA
notification obligation: Corporation;
(iii) Boehringer Ingelheim Auslandsbeteiligungs
GmbH;
Boehringer Ingelheim International
GmbH;
Boehringer Ingelheim Verwaltungs
GmbH;
Dr. Karl Thomae GmbH;
C.H. Boehringer Sohn AG &
Co. KG
------------------------------------------------------ --------------------------------------------
4. Full name of shareholder(s) Boehringer Ingelheim Corporation
(if different from 3.):(iv)
------------------------------------------------------ --------------------------------------------
5. Date of the transaction 29 February 2016
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------ --------------------------------------------
6. Date on which issuer 29 February 2016
notified:
------------------------------------------------------ --------------------------------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 16%
------------------------------------------------------ --------------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- ---------------------------------- ------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
-------------- ---------------- ---------------- -------------- --------------------------- ---------------------
Indirect Direct Indirect Direct Indirect
(xi) (xii)
-------------- ------------ ------------ -------------- ------------- ------------ -------- -----------
GB00B0LCW083 0 0 40,000,000 40,000,000 0 16.67% 0
---------------- ---------------- -------------- ------------- ------------ -------- -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------ -------------- -------------------------------- ------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
---------------- -------------- -------------- -------------- ----------------------------- ---------------------
Nominal Delta
---------------- -------------- -------------- -------------- ----------------------------- ---------- ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
---------------------------------------------------------------- ----------------------------------------------------
40,000,000 16.67%
---------------------------------------------------------------- ----------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
----------------------------------------------------------------------------------------------------------------------
Boehringer Ingelheim Corporation has the following parent
undertakings:
Boehringer Ingelheim USA Corporation, a Delaware corporation
(wholly owns the voting shares in Boehringer Ingelheim
Corporation).
Boehringer Ingelheim Auslandsbeteiligungs GmbH, a German
company with limited liability (wholly owns Boehringer
Ingelheim USA Corporation).
Boehringer Ingelheim International GmbH, a German company
with limited liability (wholly owns Boehringer Ingelheim
Auslandsbeteiligungs GmbH).
Boehringer Ingelheim Verwaltungs GmbH, a German company
with limited liability (wholly owns Boehringer Ingelheim
International GmbH).
Dr. Karl Thomae GmbH, a German company with limited
liability (wholly owns Boehringer Ingelheim Verwaltungs
GmbH).
C.H. Boehringer Sohn AG & Co. KG, a German limited partnership
(wholly owns Dr. Karl Thomae GmbH).
Proxy Voting:
----------------------------------------------------------------------------------------------------------------------
10. Name of the proxy holder: N/A
--------------------------------------------------------------------------------- -----------------------------------
11. Number of voting rights proxy holder
will acquire:
--------------------------------------------------------------------------------- -----------------------------------
12. Date on which proxy holder will
acquire voting rights:
February 29, 2016 08:59 ET (13:59 GMT)
--------------------------------------------------------------------------------- -----------------------------------
13. Additional information:
None
---------------------------------------------------------------- ----------------------------------------------------
14. Contact name: Stephan Bach (Corporate Treasury)
Eric Humbert (Corporate Treasury)
---------------------------------------------------------------- ----------------------------------------------------
15. Contact telephone number: Stephan Bach: +49 (6132)
77-3032
Eric Humbert: +49 (6132)
77-90717
---------------------------------------------------------------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUKVORNWAUUAR
(END) Dow Jones Newswires
February 29, 2016 08:59 ET (13:59 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024